Clinical Trial Detail

NCT ID NCT01625936
Title CRLX101 Plus Bevacizumab in Advanced RCC
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

renal cell carcinoma

Therapies

Bevacizumab

CRLX101

Age Groups: adult

No variant requirements are available.